Open Access

MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2

  • Authors:
    • Yanli Wang
    • Fengcai Li
    • Dandan Ma
    • Yuhua Gao
    • Runpu Li
    • Yingjie Gao
  • View Affiliations

  • Published online on: August 26, 2019     https://doi.org/10.3892/mmr.2019.10616
  • Pages: 3519-3526
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cisplatin has been widely used as a conventional treatment for patients with non‑small cell lung cancer (NSCLC). However, primary and acquired cisplatin resistances are frequently developed during the treatment of patients with NSCLC, leading to an increased mortality rate. Accumulating evidence demonstrated that aberrantly expressed microRNAs (miRs) are involved in the development of chemoresistance. In the present study, sensitivity of NSCLC cells to cisplatin was identified to increase following overexpression of miR‑608. Conversely, sensitivity to cisplatin was reduced following miR‑608 knockdown. Reverse transcription‑quantitative PCR and western blotting analyses identified that TEA domain transcription factor 2 (TEAD2), a key regulator of cell stemness, was negatively regulated by miR‑608 in NSCLC cells. By repressing TEAD2, miR‑608 decreased the expression level of several target genes of the Hippo‑yes‑associated protein signaling pathway. Furthermore, TEAD2 mRNA was confirmed to be targeted by miR‑608 in NSCLC cells via a dual‑luciferase reporter assay. Importantly, the increased cisplatin sensitivity induced by miR‑608 overexpression was reversed by transfection of TEAD2 in NSCLC cells. The present data suggested that miR‑608 may represent a novel candidate biomarker for the evaluation of cisplatin sensitivity in patients with NSCLC.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Ma J, Ward EM, Smith R and Jemal A: Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 119:1381–1385. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Laack E, Bokemeyer C and Hossfeld DK: Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int. 105:249–254. 2008.PubMed/NCBI

4 

Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, Takahata S, Toma H, Nagai E and Tanaka M: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 8:1067–1074. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Allen KE and Weiss GJ: Resistance may not be futile: MicroRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Jin Z, Guan L, Song Y, Xiang GM, Chen SX and Gao B: MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. Eur Rev Med Pharmacol Sci. 20:1080–1086. 2016.PubMed/NCBI

12 

Wu S, Yuan W, Shen Y, Lu X, Li Y, Tian T, Jiang L, Zhuang X, Wu J and Chu M: The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type. Tumour Biol. 39:10104283177038192017. View Article : Google Scholar : PubMed/NCBI

13 

Liu H, Zhou Y, Liu Q, Xiao G, Wang B, Li W, Ye D and Yu S: Association of miR-608 rs4919510 polymorphism and cancer risk: A meta-analysis based on 13,664 subjects. Oncotarget. 8:37023–37031. 2017.PubMed/NCBI

14 

Othman N, In LL, Harikrishna JA and Hasima N: Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS One. 8:e817352013. View Article : Google Scholar : PubMed/NCBI

15 

Mesrouze Y, Bokhovchuk F, Meyerhofer M, Fontana P, Zimmermann C, Martin T, Delaunay C, Erdmann D, Schmelzle T and Chène P: Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD. Elife. 6:e250682017. View Article : Google Scholar : PubMed/NCBI

16 

Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Landin-Malt A, Benhaddou A, Zider A and Flagiello D: An evolutionary, structural and functional overview of the mammalian TEAD1 and TEAD2 transcription factors. Gene. 591:292–303. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y and Sasaki H: Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol. 28:3177–3189. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Tian W, Yu J, Tomchick DR, Pan D and Luo X: Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci USA. 107:7293–7298. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Lin KC, Park HW and Guan KL: Regulation of the hippo pathway transcription factor TEAD. Trends Biochem Sci. 42:862–872. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Diepenbruck M, Waldmeier L, Ivanek R, Berninger P, Arnold P, van Nimwegen E and Christofori G: Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. J Cell Sci. 127:1523–1536. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:e050052015. View Article : Google Scholar :

25 

Bragado P, Armesilla A, Silva A and Porras A: Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 12:1733–1742. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Othman N and Nagoor NH: The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment. Biomed Res Int. 2014:3180302014. View Article : Google Scholar : PubMed/NCBI

27 

Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, et al: Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res. 20:837–846. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I, Shaaban AM, et al: The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget. 7:43188–43198. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM and You L: Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. Oncol Rep. 2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

30 

Happé H, van der Wal AM, Leonhard WN, Kunnen SJ, Breuning MH, de Heer E and Peters DJ: Altered Hippo signalling in polycystic kidney disease. J Pathol. 224:133–142. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P and Harrap KR: Ammine/amine platinum(IV) dicarboxylates: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 52:822–828. 1992.PubMed/NCBI

32 

Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI

33 

Bian HB, Pan X, Yang JS, Wang ZX and De W: Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 30:202011. View Article : Google Scholar : PubMed/NCBI

34 

Dong Z, Zhong Z, Yang L, Wang S and Gong Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Zhang H, Hu B, Wang Z, Zhang F, Wei H and Li L: miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1. Cancer Chemother Pharmacol. 80:973–984. 2017. View Article : Google Scholar : PubMed/NCBI

36 

Ye Z, Yin S, Su Z, Bai M, Zhang H, Hei Z and Cai S: Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget. 7:37524–37535. 2016. View Article : Google Scholar : PubMed/NCBI

37 

Yu HX, Wang XM, Han XD and Cao BF: MiR-608 exerts tumor suppressive function in lung adenocarcinoma by directly targeting MIF. Eur Rev Med Pharmacol Sci. 22:4908–4916. 2018.PubMed/NCBI

38 

Guo J, Wu Y, Yang L, Du J, Gong K, Chen W, Dai J, Li X and Xi S: Repression of YAP by NCTD disrupts NSCLC progression. Oncotarget. 8:2307–2319. 2017.PubMed/NCBI

39 

Liu AM, Poon RT and Luk JM: MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010. View Article : Google Scholar : PubMed/NCBI

40 

Lei CJ, Li L, Gao X, Zhang J, Pan QY, Long HC, Chen CZ, Ren DF and Zheng G: Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP. Cell Biochem Funct. 33:326–333. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Zhang M, Zeng J, Zhao Z and Liu Z: Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer. Mol Carcinog. 56:821–832. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 20 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, Y., Li, F., Ma, D., Gao, Y., Li, R., & Gao, Y. (2019). MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2. Molecular Medicine Reports, 20, 3519-3526. https://doi.org/10.3892/mmr.2019.10616
MLA
Wang, Y., Li, F., Ma, D., Gao, Y., Li, R., Gao, Y."MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2". Molecular Medicine Reports 20.4 (2019): 3519-3526.
Chicago
Wang, Y., Li, F., Ma, D., Gao, Y., Li, R., Gao, Y."MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2". Molecular Medicine Reports 20, no. 4 (2019): 3519-3526. https://doi.org/10.3892/mmr.2019.10616